Roivant Advances Mosliciguat to Phase 3 After Strongest PVR Reduction Yet in PH-ILD

Mosliciguat cut PVR 56.3% vs placebo in Phase 2 PH-ILD, improved 6-minute walk, and advanced to Phase 3. Shares jumped on the data.